Themis Medicare Limited (IN:THEMISMED)
:THEMISMED
Want to see IN:THEMISMED full AI Analyst Report?
THEMISMED Stock Chart & Stats
₹102.50
₹17.25(6.68%)
At close: 4:00 PM EST
₹102.50
₹17.25(6.68%)
Day’s Range― - ―
52-Week Range₹65.00 - ₹154.45
Previous CloseN/A
Volume256.77K
Average Volume (3M)6.87K
Market Cap
₹9.02B
Enterprise Value₹9.96B
Total Cash (Recent Filing)₹189.59M
Total Debt (Recent Filing)₹955.64M
Price to Earnings (P/E)22.9
Beta1.57
Next Earnings
May 30, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.48%
Share Statistics
EPS (TTM)-2.92
Shares Outstanding92,100,120
10 Day Avg. Volume6,301
30 Day Avg. Volume6,868
Financial Highlights & Ratios
PEG Ratio-1.45
Price to Book (P/B)3.39
Price to Sales (P/S)3.37
P/FCF Ratio70.80
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
High Gross Margins & Revenue ExpansionThemis reports sustained top-line expansion with high gross margins, indicating an efficient cost structure and pricing power in core products. Persistently strong gross margins support reinvestment in R&D and manufacturing, provide a cushion against raw material swings, and underpin durable operating leverage as revenue scales.
Stable Balance Sheet With Managed LeverageA healthy equity ratio and controlled debt-to-equity give Themis financial flexibility to fund growth initiatives or absorb shocks. Managed leverage reduces refinancing risk and supports capital allocation for capacity expansion or selective M&A, strengthening the company’s ability to execute a long-term specialty/generic pharma strategy.
Improving Operating Cash Flow And FCF RecoveryOperating cash flows have trended upward with free cash flow recovering from prior negatives, improving the firm’s internal funding capacity. Stronger cash generation enhances self-funding of capex, reduces reliance on external financing, and supports sustainable investment in manufacturing and commercial channels over the medium term.
Bears Say
Volatile Net Profit MarginsReported net margin volatility signals uneven expense control, pricing pressure, or periodic one-offs that impair earnings quality. Persistent variability in net profits undermines predictability of returns, complicates capital allocation and investor planning, and may limit the company’s ability to consistently convert operational strength into sustained bottom-line growth.
Inconsistent Cash ConversionInconsistencies between reported net income and free cash flow indicate working-capital swings or timing differences that reduce cash reliability. This can constrain investment pacing, increase the need for short-term financing, and weaken resilience to demand shocks, making long-term planning and organic growth funding more challenging.
Recent Top-line WeaknessA recent ~22% reported revenue decline raises concern about demand erosion, contract losses, or market share pressures. Even with historical growth and margin strength, sustained top-line weakness risks eroding scale advantages, pressuring margins, and requiring strategic responses (product, pricing, or market diversification) to restore durable growth.
Themis Medicare Limited News
THEMISMED FAQ
What was Themis Medicare Limited’s price range in the past 12 months?
Themis Medicare Limited lowest stock price was ₹65.00 and its highest was ₹154.45 in the past 12 months.
What is Themis Medicare Limited’s market cap?
Themis Medicare Limited’s market cap is ₹9.02B.
When is Themis Medicare Limited’s upcoming earnings report date?
Themis Medicare Limited’s upcoming earnings report date is May 30, 2026 which is in 8 days.
How were Themis Medicare Limited’s earnings last quarter?
Themis Medicare Limited released its earnings results on Feb 13, 2026. The company reported ₹1.096 earnings per share for the quarter, beating the consensus estimate of N/A by ₹1.096.
Is Themis Medicare Limited overvalued?
According to Wall Street analysts Themis Medicare Limited’s price is currently Overvalued.
Does Themis Medicare Limited pay dividends?
Themis Medicare Limited pays a Annually dividend of ₹0.5 which represents an annual dividend yield of 0.48%. See more information on Themis Medicare Limited dividends here
What is Themis Medicare Limited’s EPS estimate?
Themis Medicare Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Themis Medicare Limited have?
Themis Medicare Limited has 92,100,120 shares outstanding.
What happened to Themis Medicare Limited’s price movement after its last earnings report?
Themis Medicare Limited reported an EPS of ₹1.096 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 0.41%.
Which hedge fund is a major shareholder of Themis Medicare Limited?
Currently, no hedge funds are holding shares in IN:THEMISMED
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Themis Medicare Limited
Themis Medicare Limited, together with its subsidiaries, manufactures and sells pharmaceutical products in India and internationally. It offers active pharmaceutical ingredients and formulations for use in various therapeutic areas, including anti-infective, antimalarial, anti-tuberculosis, cardiology, health and nutrition, oncology, ophthalmology, and pain management. The company was formerly known as Themis Chemicals and changed its name to Themis Medicare Limited in 2001. Themis Medicare Limited was incorporated in 1969 and is headquartered in Mumbai, India.
Technical Analysis
Bliss Gvs Pharma Limited
―
Jagsonpal Pharmaceuticals Ltd.
―
Kopran Limited
―
Lincoln Pharmaceuticals Ltd
―
Wanbury Limited
―